改善炎症性皮肤疾病的全身治疗选择:临床需求调查
Nicholas D Brownstone1, Aaron S Farberg2,3, Graham H Litchman4
1Department of Dermatology, Temple University Hospital, Philadelphia, Pennsylvania.
JAAD international
|May 22, 2024
概括
临床医生通常需要多种系统性治疗牛皮 (PSO) 和亚托皮炎 (AD) 由于经验治疗选择. 超过90%的受访皮肤科医生非常希望使用分子测试来指导治疗选择.
科学领域:
- 皮肤病学 皮肤病学
- 药物基因组学 药物基因组学
- 临床试验设计 临床试验设计
背景情况:
- 对牛皮 (PSO) 和亚托皮性皮炎 (AD) 的实证治疗选择可以延迟疾病控制并增加医疗保健成本.
- 目前的临床实践缺乏常规分子测试,以指导PSO和AD的全身治疗选择.
- 该研究解决了在这些常见的皮肤病中改善个性化治疗策略的需求.
研究的目的:
- 为了调查临床医生如何选择PSO和AD患者的全身疗法,而没有分子诊断工具.
- 评估当前实证治疗方法所必需的药物切换频率.
- 测量临床医生对分子测试的兴趣,以优化治疗决策.
主要方法:
- 在2022年皮肤病学会议的与会者进行了一项20个问题的调查.
- 该调查评估了临床医生对AD和PSO系统治疗的策略.
- 达到了64%的应答率 (265/414),提供了关于治疗决策的数据.
主要成果:
- "报告的疗效"是影响治疗选择的主要因素 (P < .001).
- 62%的临床医生报告说,为了有效性,他们需要2种或更多的全身药物.
- 超过90%的受访者对指导治疗选择的分子测试表达了强烈的兴趣.
结论:
- 临床医生目前依赖经验方法来选择PSO和AD疗法,通常需要多种药物试验.
- 对于分子测试来个性化和优化系统性治疗选择,存在着大量未满足的需求和强烈的需求.
- 实施分子诊断可以改善治疗结果,并降低与非最佳治疗选择相关的医疗保健成本.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115


